Trial Profile
Study of NT-814 in women with bothersome post- menopausal symptoms
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Nov 2018
Price :
$35
*
At a glance
- Drugs Elinzanetant (Primary)
- Indications Sex hormone disorders; Vasomotor symptoms
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 26 Nov 2018 New trial record
- 06 Oct 2018 Results presented at the North American Menopause Society 2018 Annual Meeting